Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

or and 5-HT6 antagonist programs. The

Company expects the savings from these initiatives to be in the range

of $2-3 million on an annualized basis.

-- Receipt of Nasdaq Notification. On April 2, 2008, the Company received

written notification from Nasdaq that, as of December 31, 2007, the

Company was not in compliance with the minimum $10.0 million

stockholders' equity requirement for continued listing under

Marketplace Rule 4450(a)(3). As required by Nasdaq, the Company has

submitted a plan to achieve and sustain compliance with all of The

Nasdaq Global Market listing requirements and the time frame required

to complete that plan.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call on May 14, 2008, at 9:00 a.m. EDT to discuss the Company's first quarter 2008 financial results. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Wednesday, May 14, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4441

Telephone (international): 617.597.5396

Participant Passcode: 80809977

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, May 14, 2008, until Wednesday, May 21, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 14991737. An audio replay of the conference call will also be available under the "Investors" section of the Company's website
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/25/2014)... 2014 Research and Markets has ... Product , Research Area & by End User - ... In this report, the global epigenetics ... areas, and end users. The product segments of the ... & consumables, kits, and reagents. The subsegments of the ...
(Date:10/22/2014)... New test innovations will be the source ... test industry, especially as companies struggle with reimbursement challenges, ... than 25 testing innovations in important disease areas in ... products. Kalorama details the new approaches its biennial survey of ... Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... of senior living community, LISLE, Ill., ... leading,faith-based continuing care retirement community located in ... newly redesigned web site,( http://www.VillaStBen.org ). The ... residents, and provides in-depth information and support ...
... GenVault Corporation today,announces Paul J. Mirabella, Chairman and ... Board of Directors. Mr. Mirabella has more than ... Healthcare where he held,leadership roles in technology, marketing ... in diagnostics and the healthcare,market, he will help ...
... Restore Shareholder Value Following NEBIDO(R) ... ... IDEV ) today announced that Glenn L. Cooper,MD, its chairman and chief ... challenges,it faces as a result of the recent delay in the approval ...
Cached Biology Technology:Villa St. Benedict Announces New Web Site 2Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors 2Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4
(Date:10/25/2014)... Oct. 23, 2014 Research and Markets ... in Europe 2014-2018" report to their offering. ... assess individuals on the basis of their physical or ... both physiological traits such as fingerprints, face recognition, DNA, ... traits such as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/22/2014)... identity analyst firm Acuity Market Intelligence forecasts that in ... have a chip-based National eID card, including near-complete regional ... Asia , with its vast population, is expected ... of all National eID cards issued between 2014 and ... National eID Industry Report: 2014 Edition" — projects ...
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... threatened forest frogs to disappear, paving the way for ... have revealed. The study, carried out by the ... to palm oil plantations are causing threatened forest dwelling ... habitat that is important for the conservation of threatened ...
... the most commonly cultivated cacao plant in the world ... this week. Researchers have utilised high quality DNA sequences to ... markers that can lead to higher yielding cocoa plants that still ... the cacao tree ( Theobroma cacao L. ...
... the University of Georgia, Athens, have identified a strong ... pathogens on poultry farms, and later downstream at the ... published ahead of print in the journal Applied ... reducing foodborne pathogen loads on broiler chicken farms would ...
Cached Biology News:Threatened frogs palmed off as forests disappear 2Genome hints at markers for higher-producing, better-tasting chocolate 2Investigators link poultry contamination on farm and at processing plant 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: